A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an…
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea
- Promotore
- Merck Sharp & Dohme LLC (MSD)
- Acronimo
- MK3543-006
- Struttura
- Ematologia
- Sperimentatore principale
- Marchetti Monia
- Stato arruolamento
- Arruolamento in corso
- Unit di ricerca
- Fase I